A treat-to-target urate management strategy does not improve kidney outcome in patients with chronic kidney disease and asymptomatic hyperuricemia: a target trial emulation

Annals of Medicine 2026 Open access

Read full text
Authors: Qi Liu, Yibo Hu, Ran He, Zihan Fang, Wenfang He, Danna Zheng, Juan Jin, Qiang He
DOI: 10.1080/07853890.2026.2668232
Cited by: 1
References: 32

Abstract

BACKGROUND: Whether a treat-to-target urate management strategy improves kidney outcomes in patients with chronic kidney disease (CKD) and asymptomatic hyperuricemia initiating urate-lowering therapy (ULT) remains uncertain, despite current guidelines. METHODS: This target trial emulation (TTE) study included 2092 adults with stage G3-G4 CKD and asymptomatic hyperuricemia who initiated ULT at Zhejiang Provincial People's Hospital between 2018 and 2024. Using a clone-censor-weight (CCW) approach to address biases, we compared a treat-to-target strategy (targeting serum urate

Fields of Study & Subjects

Gout Hyperuricemia Uric Acid Chronic Kidney Disease and Diabetes Kidney Stones and Urolithiasis Treatments

Publication details

Journal / source
Annals of Medicine
Publisher
Informa UK Limited
Volume
58
Issue
1
Pages
2668232–2668232
Publication date
7 May 2026
Language
EN